Scotland, GrahamTsehaye, MekazinStyles, CarolineLogue, JenniferSammons, EmilyZayed, MohammedEmberson, JonathanWade, RachelWallendszus, KarlStevens, WillCretney, RosannaHarding, SimonLeese, GrahamCurrie, GemmaArmitage, JanePreiss, DavidLENS collaborative group2025-08-152025-08-152025-09Scotland, G, Tsehaye, M, Styles, C, Logue, J, Sammons, E, Zayed, M, Emberson, J, Wade, R, Wallendszus, K, Stevens, W, Cretney, R, Harding, S, Leese, G, Currie, G, Armitage, J, Preiss, D & LENS collaborative group 2025, 'Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy : an economic evaluation based on data from the LENS trial', Diabetic Medicine, vol. 42, no. 9, e70098. https://doi.org/10.1111/dme.700980742-3071https://hdl.handle.net/2164/25861Open Access via the Wiley agreement We are very grateful to all participants, staff at participating NHS Scotland sites, and members of the Steering Committee and Data Monitoring Committee. We greatly appreciate the support of NHS Scotland’s Diabetic Eye Screening program, the Scottish Care Information Diabetes Collaboration (SCI Diabetes), Public Health Scotland’s electronic Data Research and Innovation Service (eDRIS), the Health Informatics Centre at the University of Dundee, and PCI Pharma Services. We are also very grateful to Prof Sobha Sivaprasad, University College London, for providing clinical expert opinion on economic modelling assumptions.141292387engSDG 3 - Good Health and Well-beingDiabetic RetinopathyFenofibrateCost-effectiveness analysisR Medicine (General)R1Journal article10.1111/dme.70098429